Category: Cannabis Law Journal

The laboratory is both one of the most active and one of the most critical rooms in a GMP facility. The laboratory generates all the quality control reporting necessary to prove the quality of your final products. Laboratories have diverse diagnostic equipment pertinent to your operation, and depending on your budget, these tools can increase self-sufficiency and accuracy. Organizing the lab right is another step in your Good Manufacturing Practice (GMP) approval process that will guide your product quality and innovations.

The UK are seen as pioneers in climate action and are vocal supporters of the Paris Agreement. A backdated agreement to 1990 sees the Government committed to reducing emissions by a whopping 78% by the year 2035. This would be a monumental achievement but nobody is addressing the elephant in the room, cannabis.

More and more US states are taking steps to ban the psychoactive cannabinoid Delta-8 THC. This compound has a similar structure to the conventional cannabinoid Delta-9 THC and has been increasingly used in commercial cannabis products in recent months.

The recent announcement by the state of Colorado proposed that all marijuana concentrates in electronic cannabais delivery systems (ECDS) must be tested for heavy metal contaminants in the emitted aerosol

There are hundreds, perhaps thousands, of companies involved in the Δ8THC segment of the hemp industry. Due to an oversupply in the market of hemp biomass, hemp extract, and CBD, we have seen a precipitous drop in both prices and profits for these commodities. In contrast, Δ8THC sales are exploding. For this reason, some contend that Δ8THC is singlehandedly saving the hemp industry from economic annihilation. Others, however, contend that Δ8THC is dangerous to the hemp industry’s reputation.

Given the relatively nascent nature of cannabis regulation, new cannabinoid discoveries and trends are happening with greater speed. Issues surrounding naturally occurring and synthetically derived cannabinoids are mounting and lines being drawn. Ultimately, products with intoxicating cannabinoids will find themselves in the marijuana regulated space while consumers will regularly find hemp products on mainstream retail shelves.

The short answer is that it depends on the use. Mexico is in the process of cannabis legalization. As of today, the harvesting, growing, transporting, and sale of adult use cannabis is expressly prohibited by law and sanctioned by the Federal Criminal Code.

As Congress continues to deliberate the federal legalization of marijuana, the cannabis industry continues to face scrutiny from the IRS under Section 280E of the Internal Revenue Code (Code).

In an industry that runs on innovation and differentiation, a cannabis brand’s identity is among its most valuable—and most prone to copying—assets. It’s a common myth that cannabis industry brands cannot get trademark protection. In fact, many cannabis-related trademarks are registered with the U.S. Patent and Trademark Office (USPTO), including U.S. Weed Channel, MedMen, Cheech’s Private Stash, and GOT GUMMIES? to name a few.

On April 20, 2021, Denver Mayor, Michael Hancock, signed the Marijuana Omnibus Bill and Marijuana Hospitality Bill into law, which make significant changes to Denver’s current cannabis laws.  These changes directly address hot-button items such as social equity and permanently implement the relaxation of certain regulations initially implemented for safety purposes during the pandemic.  These changes are long overdue and signify that Denver may be assuming the mantle of trendsetter for a post COVID-19 cannabis industry.

Recently, when dismissing a job-applicant’s disability discrimination claims brought under California state law, the U.S. District Court for the Central District of California issued two welcome reminders to employers.  First, an employer can condition an offer of employment on the completion of a preemployment drug screen, including a test for marijuana. This is true even though California has legalized marijuana for both recreational and medical purposes.  Second, an employer is not under any obligation to engage in the interactive process before an applicant passes a pre-employment drug screen.

Today, the U.S. Federal Trade Commission (FTC) announced a settlement in its most recent law enforcement action in its ongoing efforts to monitor the marketplace regarding misleading cannabidiol (CBD) product claims. The action targets Kushly Industries LLC (Kushly) and the company’s sole officer for allegedly making false or unsupported health benefit claims about Kushly’s CBD product.